Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...
"Prior 28-day Phase 1 data demonstrated encouraging tolerability with the tablet formulation, as well as promising reductions in body weight. We believe VK2735's clinical results to-date suggest a ...
Viking Therapeutics (VKTX) announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735 ... is the most comprehensive data set of sell side analysts and hedge ...
Viking Therapeutics has announced the start of a Phase II clinical trial for VK2735, an oral tablet aimed at treating metabolic disorders, such as obesity. The VENTURE-Oral Dosing Trial is a ...
The data released by Viking ... to move forward on the clinical path with the Food and Drug Administration (FDA) later this year for an injectable version of VK2735 and that they expect to ...
6don MSN
CEO Brian Lian highlighted 2024 as an exceptionally busy year, with successful results from four studies, including the Phase 2 VENTURE trial for subcutaneous VK2735, which demonstrated up to 14.7% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback